Sugi Predict

Sugi Predict / Compounds / SCHEMBL234633

SCHEMBL234633

SCHEMBL234633

CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ NR5A2 O00482 1/20 0.59
▸ NR5A1 Q13285 1/20 0.59
▸ MAPT P10636 1/20 0.55
▸ RECQL P46063 1/20 0.48
▸ ADRA1D P25100 1/20 0.48
▸ PTAFR P25105 1/20 0.48
▸ HTR1D P28221 1/20 0.48
▸ HTR2C P28335 1/20 0.48
▸ ADRA1B P35368 1/20 0.48
▸ DRD3 P35462 1/20 0.48
▸ TMEM97 Q5BJF2 1/20 0.48
▸ FABP3 P05413 1/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ PRKD3 O94806 1/20 0.43
▸ PRKCG P05129 1/20 0.43
▸ PRKCB P05771 1/20 0.43
▸ PRKCA P17252 1/20 0.43
▸ PRKCH P24723 1/20 0.43
▸ AKT1 P31749 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27219506 1.00 SMN1; SMN2 (0.59) SMN1; SMN2NR5A2NR5A1MAPTRECQL
Tetrabuthylammonium SCHEMBL2064523 0.93 SMN1; SMN2 (0.62) SMN1; SMN2NR5A2NR5A1MAPTRECQL
SCHEMBL6285425 0.91 SMN1; SMN2 (0.50) SMN1; SMN2NR5A2NR5A1MAPTRECQL
SCHEMBL14346443 0.89 FABP3 (0.59) SMN1; SMN2NR5A2NR5A1MAPTRECQL
SCHEMBL21523585 0.89 FABP3 (0.59) SMN1; SMN2NR5A2NR5A1MAPTRECQL
SCHEMBL1521671 0.84 PRKCA (0.42) SMN1; SMN2NR5A2NR5A1MAPTFABP3
SCHEMBL29363340 0.83 SMN1; SMN2 (0.80) SMN1; SMN2NR5A2NR5A1MAPTRECQL
SCHEMBL234142 0.80 ENPP2 (0.51) SMN1; SMN2FABP3PRKCA
SCHEMBL2030912 0.80 SMN1; SMN2 (0.88) SMN1; SMN2NR5A2NR5A1MAPTRECQL
SCHEMBL7513216 0.80 SMN1; SMN2 (0.88) SMN1; SMN2NR5A2NR5A1MAPTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1602 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109732-A1 LIPID AMINES MODERNATX INC (US) 2026-04-23 — — US claimed
EP-3977137-B1 DETECTION OF ANALYTES BY NANOPORE WITHOUT USING ELECTRODES NANJING UNIVERSITY (CN) 2026-04-01 — — EP claimed
EP-4705012-A1 HYBRID TRIBLOCK COPOLYMER MEMBRANE COMPOSITIONS AND METHODS FOR NANOPORE SEQUENCING F. Hoffmann-La Roche AG (CH) 2026-03-11 — — EP claimed
EP-4689180-A1 MODULATION OF TARGET MOLECULE-LIPID BILAYER INTERACTIONS F. Hoffmann-La Roche AG (CH) 2026-02-11 — — EP claimed
EP-4683666-A1 PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS ModernaTX, Inc. (US) 2026-01-28 — — EP claimed
EP-4683665-A1 PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS ModernaTX, Inc. (US) 2026-01-28 — — EP claimed
EP-4683667-A1 PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS ModernaTX, Inc. (US) 2026-01-28 — — EP claimed
US-20250361502-A1 Promoters And Compositions UNIV OXFORD INNOVATION LTD (GB) 2025-11-27 — — US claimed
WO-2025227058-A1 DETERGENT-FREE NANOPORE DELIVERY Roche Sequencing Solutions, Inc. (US) 2025-10-30 — — WO claimed
EP-4620970-A1 PORIN MONOMER, PORIN, MUTANT THEREOF, AND USE THEREOF BGI Shenzhen (CN) 2025-09-24 — — EP claimed
US-8293339-B2 Droplet bilayers SRI INTERNATIONAL, INC. (US) 2012-10-23 — — US claimed
US-20120142044-A1 METHODS FOR IONOPHORICALLY SCREENING PORE FORMING BACTERIAL PROTEIN TOXINS AND RECEPTORS CUPPOLETTI JOHN (US) 2012-06-07 — — US claimed
US-8148172-B2 Methods for ionophorically screening pore forming bacterial protein toxins and receptors CUPPOLETTI JOHN (US) 2012-04-03 — — US claimed
EP-1364948-B1 Biomimetic system of lipid membranes bonded to a substrate KNOLL WOLFGANG (AT) 2010-11-10 — — EP claimed
WO-2008094204-A9 METHODS FOR IONOPHORICALLY SCREENING PORE FORMING BACTERIAL PROTEIN TOXINS AND RECEPTORS CUPPOLETTI JOHN (US) 2008-11-20 — — WO claimed
WO-2008094204-A2 METHODS FOR IONOPHORICALLY SCREENING PORE FORMING BACTERIAL PROTEIN TOXINS AND RECEPTORS CUPPOLETTI JOHN (US) 2008-08-07 — — WO claimed
US-20080138839-A1 Forming membrane comprising lipid and receptor, contacting with pore forming bacterial protein toxin and ion solution, and measuring ion flow through the membrane; kits CUPPOLETTI JOHN 2008-06-12 — — US claimed
US-20060292637-A1 Biomimetic systems consisting of lipid membranes bound to an electrically conducting substrate MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) 2006-12-28 — — US claimed
US-20040023304-A1 Biomimetic systems consisting of lipid membranes bound to a substrate MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2004-02-05 — — US claimed
EP-1364948-A2 Biomimetic system of lipid membranes bonded to a substrate Max Planck Society, Max Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2003-11-26 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060292637-A1 Biomimetic systems consisting of lipid membranes bound to an electrically conducting substrate EPCAM, HLCS, DBI SMN1; SMN2 3846/4885NR5A2 4302/4885NR5A1 3931/4885
US-20260109732-A1 LIPID AMINES LDLR, NPC1, PHOSPHO1 SMN1; SMN2 1002/4885NR5A2 435/4885NR5A1 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.